Effects of laropiprant, a selective prostaglandin d2 receptor 1 antagonist, on the pharmacokinetics of rosiglitazone

Cardiovascular Therapeutics

Volumn 27, Issue 4, 2009, Pages 239-245

  Schwartz, Jules I ^a   Stroh, Mark ^a   Gao, Bing ^b   Liu, Fang ^a   Rosko, Kimberly ^a   Zajic, Stefan ^a   Meehan, Alan J ^a   Ruckle, Jon ^c   Lai, Eseng ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b AMGEN INC   (United States)

^c Pacific Pharma Group   (United States)

Author keywords

Drug drug interactions; Laropiprant; Pharmacodynamics; Pharmacokinetics; Rosiglitazone

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOCHROME P450 2C8; LAROPIPRANT; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME SUBSTRATE; FATIGUE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE;

ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INDOLES; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; THIAZOLIDINEDIONES;

EID: 70449467112     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00104.x     Document Type: Article

References (20)

1. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipemia. In : Hardman JG, Limbird LE, Gillman AG, editors. The pharmacological basis of therapeutics, 10th edition. New York : Goodman and Gillman, 2001 971 1002.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002 106 : 3143 3421.
3. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000 2 : 36 46.
4. Morrow JD, Parsons WG 3rd., Roberts LJ 2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989 38 : 263 274.
5. Heavey DJ, Lumley P, Barrow SE, Murphy MB, Humphrey PP, Dollery CT. Effects of intravenous infusions of prostaglandin D2 in man. Prostaglandins 1984 28 : 755 767.
6. Paolini JF, Bays HE, Ballantyne CM, Davidson M, Pasternak R, Maccubbin D, Norquist JM, Lai E, Waters MG, Kuznetsova O, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008 26 : 547 560.
7. Felts AS. Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides. Curr Top Med Chem 2008 8 : 1310.
8. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008 101 : 625 630.
9. Lai E, Wenning LA, Crumley TM, De L, I, Liu F, de Hoon JN, Van Hecken A, Depre M, Hilliard D, Greenberg H, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008 83 : 840 847.
10. Chang SW, Reddy V, Pereira T, Dean BJ, Xia YQ, Seto C, Franklin RB, Karanam BV. The pharmacokinetics and disposition of MK-0524, a Prostaglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica 2007 37 : 514 533.
11. Karanam B, Madeira M, Bradley S, Wenning L, Desai R, Soli E, Schenk D, Jones A, Dean B, Doss G, et al. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Drug Metab Dispos 2007 35 : 1196 1202. (Pubitemid 46956442)
12. Van Hecken A, Depre M, De L, I, Thach C, Oeyen M, Van Effen J, Laethem T, Mazina K, Crumley T, Wenning L, et al. The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol 2007 63 : 135 141.
13. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000 22 : 1151 1168.
14. Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000 54 : 333 337.
15. Lai E, Wenning LA, Crumley TM. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008 83 : 840 847.
16. Huang S-M, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Raman K, Baweja RK, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008 48 : 662 670.
17. Kim KA, Park PW, Kim KR, Park JY. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. Br J Clin Pharmacol 2007 63 : 339 345.
18. Mistry GC, Bergman AJ, Luo W, Cilissen C, Haazen W, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, doses not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007 47 : 159 164.
19. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999 48 : 424 432.
20. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005 45 : 68 78.